What question did this study set out to answer?

To compare the therapeutic effects of the non-sulphydryl ACE inhibitor spirapril and the sulphydryl-containing ACE inhibitor zofenopril on post-infarction cardiac remodelling in rats with heart failure.

November 1, 1991Cardiovascular Research

Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril

View Full Paper

Ask AI

Bookmark

Why the study?

Does spirapril or zofenopril improve cardiac remodelling in rats with experimental myocardial infarction?

Key Points

To compare the therapeutic effects of the non-sulphydryl ACE inhibitor spirapril and the sulphydryl-containing ACE inhibitor zofenopril on post-infarction cardiac remodelling in rats with heart failure.
Normotensive male Wistar rats (220–240 g) underwent left coronary artery ligation to induce myocardial infarction, while sham-operated rats served as controls.
Immediately following surgery, animals received spirapril (2–2.5 mg/kg/day) or zofenopril (12–15 mg/kg/day) in drinking water for six weeks.
Isolated hearts were evaluated via Langendorff perfusion for heart rate and left ventricular pressure at baseline and during 6 nM isoprenaline stimulation, alongside heart and lung mass assessments.
Both spirapril and zofenopril significantly attenuated the myocardial infarction-induced increases in left ventricular cavity volume, total heart weight, and lung weight.
No significant differences in ventricular enlargement or cardiopulmonary weight reductions were observed between spirapril and zofenopril treatments.
Myocardial infarction significantly reduced left ventricular pressure and heart rate; both ACE inhibitors significantly restored heart rate compared to untreated controls without altering left ventricular pressure.

Structured PICO

Does spirapril or zofenopril improve cardiac remodelling in rats with experimental myocardial infarction?

Population

Normotensive male Wistar rats (220-240 g) with experimental myocardial infarction induced by left coronary artery ligation

Intervention

Spirapril (2-2.5 mg/kg/d) or zofenopril (12-15 mg/kg/d) added to drinking water for six weeks

Comparator

Untreated infarcted animals and sham-operated controls

Outcome

Cardiac remodelling (left ventricular cavity volume, heart and lung weights, heart rate, left ventricular pressure) at six weekssurrogate

Both spirapril and zofenopril similarly attenuate ventricular enlargement and cardiac hypertrophy in a rat model of myocardial infarction, suggesting the sulphydryl moiety of zofenopril does not provide additional benefit for these outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Similar remodeling attenuation by both ACE inhibitors in rat MI; leaves open whether sulphydryl moiety confers benefit in human heart failure.

Cite This Study

Wijngaarden et al. (1991) studied this question.

synapsesocial.com/papers/6a87c55570098fa105bb5648 https://doi.org/10.1093/cvr/25.11.936

View Full Paper

Ask AI

Bookmark

Implication

Similar remodeling attenuation by both ACE inhibitors in rat MI; leaves open whether sulphydryl moiety confers benefit in human heart failure.

Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider